Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.

Michels, Renée Else; De Francesco, Maria; Mahajan, Koshu; Hengstman, Gerald J D; Schiffers, Krijn M H; Budhia, Sangeeta; Harty, Gerard; Krol, Marieke

Michels, Renée Else; De Francesco, Maria; Mahajan, Koshu; Hengstman, Gerald J D; Schiffers, Krijn M H; Budhia, Sangeeta; Harty, Gerard; Krol, Marieke.

Afiliação

Michels RE; IQVIA, Real World Evidence Solutions, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands.
De Francesco M; IQVIA, Real World Insights, Da Vincilaan 7, 1930, Zaventem, Belgium.
Mahajan K; IQVIA, Real World Insights, Gurgaon, India.
Hengstman GJD; Department of Neurology, Catharina Hospital, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands.
Schiffers KMH; Merck B.V., Tupolevlaan 41-61, 1119 NW, Schiphol-Rijk, The Netherlands.
Budhia S; PAREXEL International, PAREXEL Access Consulting, London, UK.
Harty G; EMD Serono, a business of Merck KGaA, Boston, MA, USA.
Krol M; IQVIA, Real World Evidence Solutions, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands. Marieke.Krol@iqvia.com.

Appl Health Econ Health Policy ; 18(1): 141, 2020 Feb.

Article em En | MEDLINE | ID: mdl-31939112

RESUMO

The second author's name should be "Maria De Francesco" rather than "Maria de Fransesco".

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: Appl Health Econ Health Policy Assunto da revista: SAUDE PUBLICA / SERVICOS DE SAUDE Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google